Akebia Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, announced that CEO John P. Butler will present at the 40th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, announced that CEO John P. Butler will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 4:30 p.m. ET. The presentation will be virtual, and an audio replay will be available on Akebia's investor website for 30 days post-event. Founded in 2007 and headquartered in Cambridge, Massachusetts, Akebia aims to enhance the lives of those impacted by kidney disease.
Details
News Market Reaction – AKBA
The recorded move for AKBA in the trading session of this news was -3.67%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 4, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 4:30 p.m. ET.
An audio replay of the presentation will be available through the Investors section of Akebia's website at https://ir.akebia.com for approximately 30 days following the conference.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
Mcarrasco@akebia.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-40th-annual-jp-morgan-healthcare-conference-301452956.html
SOURCE Akebia Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.